Company
Headquarters: Shanghai, China
Employees: 227
CEO: Dr. Kerry Levan Blanchard M.D., Ph.D.
HK$21.78 Billion
HKD as of July 1, 2025
US$2.77 Billion
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $309.91 B |
| Vertex Pharmaceuticals Incorporated | $117.36 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $59.14 B |
| Marinomed Biotech AG | $58.56 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $699.59 B |
| Johnson & Johnson | $374.29 B |
| AbbVie | $336.94 B |
| Novo Nordisk | $309.91 B |
| UnitedHealth Group | $279.90 B |
Everest Medicines Limited, a clinical-stage biopharmaceutical company, focuses on licensing, developing, and commercializing therapies for addressing critical unmet medical needs in Greater China and other Asia Pacific markets. It has a portfolio of eight clinical-stage drug candidates for the treatment of oncology, immunology, cardio-renal disease, and infectious diseases. Everest Medicines Limited was founded in 2017 and is headquartered in Shanghai, China.
| Last Financial Reports Date | June 30, 2020 |
| Revenue TTM | HK$773.5 M |
| EBITDA | HK$-733,430,197 |
| Gross Profit TTM | HK$578.9 M |
| Profit Margin | -147.36% |
| Operating Margin | -26.77% |
| Quarterly Revenue Growth | 246.20% |
Everest Medicines Ltd has the following listings and related stock indices.
Stock: HKEX: 1952 wb_incandescent
Stock: FSX: 6HN wb_incandescent